Get the Stockscreener App
0.4007
0.65%
0.0026
After Hours:
.41
0.0093
+2.32%
Athira Pharma Inc stock is traded at $0.4007, with a volume of 83,803.
It is up +0.65% in the last 24 hours and up +1.11% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$0.3981
Open:
$0.398
24h Volume:
83,803
Relative Volume:
0.16
Market Cap:
$15.80M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-0.1297
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
+2.22%
1M Performance:
+1.11%
6M Performance:
-14.38%
1Y Performance:
-86.60%
1-Day Range:
$0.39
$0.4114
1-Week Range:
$0.3795
$0.4122
52-Week Range:
$0.2195
$3.67
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.4007 | 15.70M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
Can machine learning forecast Athira Pharma Inc. recoveryMarket Trend Summary & Free Expert Approved Momentum Trade Ideas - Newser
Can momentum traders help lift Athira Pharma Inc.Market Volume Report & Accurate Intraday Trade Tips - Newser
Athira Pharma Inc. stock prediction for this week2025 Market WrapUp & Risk Controlled Daily Plans - Newser
Sentiment analysis tools applied to Athira Pharma Inc.Weekly Trade Recap & Precise Trade Entry Recommendations - Newser
Exit strategy if you’re trapped in Athira Pharma Inc.Insider Buying & Low Risk Entry Point Guides - Newser
Will Athira Pharma Inc. face regulatory challenges2025 Momentum Check & Reliable Breakout Stock Forecasts - sundaytimes.kr
Traders Consider Averaging Down in Athira Pharma Inc.2025 AllTime Highs & Weekly Hot Stock Watchlists - sundaytimes.kr
Will Athira Pharma Inc. rebound enough to break even2025 Technical Patterns & Fast Entry High Yield Tips - Newser
Athira Pharma presents results from Phase 1 trial of ATH-1105 at ALS Nexus - MSN
Athira Pharma shares rise 2.01% after-hours after presenting positive Phase 1 trial results for ATH-1105. - AInvest
How to monitor Athira Pharma Inc. with trend dashboardsPortfolio Gains Summary & Technical Confirmation Trade Alerts - Newser
Reversal Confirmed Athira Pharma Inc. Stock Rallies Above MAJuly 2025 Fed Impact & Weekly Watchlist of Top Performers - classian.co.kr
Athira Pharma Inc. Tests 50 Day MA After Sharp DeclineJuly 2025 Setups & High Accuracy Trade Signal Alerts - metrotimes.co.kr
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 - GlobeNewswire
Athira Pharma reports positive Phase 1 results for ALS drug candidate - Investing.com Nigeria
Novel Oral ALS Drug Candidate ATH-1105 Demonstrates Favorable Safety Profile in Early Trial - Stock Titan
Are Bears Losing Grip on Athira Pharma Inc.Portfolio Value Summary & Verified Chart Pattern Trade Signals - classian.co.kr
Athira Pharma Reports Reduced Losses Amid Financial Challenges - MSN
Athira Pharma Inc. Testing Reversal Zone on Weekly ChartRecession Risk & Accurate Technical Buy Alerts - 선데이타임즈
Analyzing Athira Pharma Inc. with risk reward ratio charts2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - Newser
What moving averages say about Athira Pharma Inc.Market Growth Summary & AI Driven Stock Movement Reports - Newser
Athira Pharma’s SWOT analysis: ALS drug developer’s stock faces pivotal moment By Investing.com - Investing.com South Africa
Athira Pharma’s SWOT analysis: ALS drug developer’s stock faces pivotal moment - Investing.com
Is Athira Pharma Inc. building a consolidation baseReal-Time Entry Signals for Top Stocks - Newser
Competitive Positioning of Athira Pharma Inc.: Is It Leading or LaggingPredictive Screener for Daily Trade Watch - Newser
Reversal indicators forming on Athira Pharma Inc. stockFree Consistent Profit Pattern Recognition Tools - Newser
Using R and stats models for Athira Pharma Inc. forecastingFree Weekly Chart Analysis With Entry Advice - Newser
What to do if you’re stuck in Athira Pharma Inc.Free Stock Selection With High Accuracy - Newser
Using fundamentals and technicals on Athira Pharma Inc.Low Risk Strategy with Smart Entry Zones - Newser
Why Athira Pharma Inc. stock attracts strong analyst attentionFast-Growing Stock Candidates - sisain.net
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Athira (ATHA) Q2 Loss Narrows 74% - The Motley Fool
Athira (ATHA) Q2 Loss Narrows 74% - The Globe and Mail
Athira Pharma Q2 net loss narrows - MarketScreener
Athira's New ALS Drug ATH-1105 Achieves Critical Safety Milestone in Phase 1 Trial, Strategic Review Continues - Stock Titan
Can technical indicators confirm Athira Pharma Inc.’s reversalWeekly Stock Market Strategy Summary - Newser
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Athira Pharma Inc Stock (ATHA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
168,901 |
| Litton Mark James | President and CEO |
Jun 30 '25 |
Option Exercise |
0.00 |
108,334 |
0 |
350,925 |
| Litton Mark James | President and CEO |
Jul 01 '25 |
Sale |
0.29 |
25,123 |
7,374 |
325,802 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
46,666 |
0 |
82,507 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jul 01 '25 |
Sale |
0.29 |
10,842 |
3,182 |
71,665 |
| Worthington Mark | General Counsel and CCO |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
120,401 |
| Worthington Mark | General Counsel and CCO |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
111,875 |
| Renninger Robert | SVP, Finance and Accounting |
Jun 30 '25 |
Option Exercise |
0.00 |
12,359 |
0 |
112,083 |
| Renninger Robert | SVP, Finance and Accounting |
Jul 01 '25 |
Sale |
0.29 |
2,897 |
850 |
109,186 |
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):